Analysis of single-cell sequencing results of an elderly patient with myeloid leukemia reveals high expression of multiple oncogenes in monocytes and hematopoietic stem cells

References

• Shallis RM, Wang R, Davidoff A, et al. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev 2019;36:70–87. DOI:10.1016/j.blre.2019.04.005. PubMed PMID: 31101526.
   PubMed Web of Science ®Google Scholar
• Ostgard LS, Norgaard JM, Severinsen MT, et al. Data quality in the Danish National Acute Leukemia Registry: a hematological data resource. Clin Epidemiol. 2013;5:335–344. DOI:10.2147/CLEP.S48411. PubMed PMID: 24039451; PubMed Central PMCID: PMC3770716.
   PubMedGoogle Scholar
• Bekadja MA, Hamladji RM, Belhani M, et al. A population-based study of the epidemiology and clinical features of adults with acute myeloid leukemia in Algeria: report on behalf of the Algerian Acute Leukemia Study Group. Hematol Oncol Stem Cell Ther. 2011;4(4):161–166. DOI:10.5144/1658-3876.2011.161. PubMed PMID: 22198187.
   PubMedGoogle Scholar
• Turbeville S, Francis KM, Behm I, et al. Prevalence and incidence of acute myeloid leukemia may be higher than currently accepted estimates among the ≥65 year-old population in the United States. Blood. 2014;124(21):958. DOI:10.1182/blood.V124.21.958.958
   Web of Science ®Google Scholar
• Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392(10147):593–606. DOI:10.1016/S0140-6736(18)31041-9. PubMed PMID: 30078459.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O'Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006;106(5):1090–1098. DOI:10.1002/cncr.21723. PubMed PMID: 16435386.
   PubMed Web of Science ®Google Scholar
• Ossenkoppele G, Lowenberg B. How I treat the older patient with acute myeloid leukemia. Blood. 2015;125(5):767–774. DOI:10.1182/blood-2014-08-551499. PubMed PMID: 25515963.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Fountzilas E, Nikanjam M, et al. Review of precision cancer medicine: evolution of the treatment paradigm. Cancer Treat Rev 2020;86:102019. DOI:10.1016/j.ctrv.2020.102019. PubMed PMID: 32251926; PubMed Central PMCID: PMC7272286.
   PubMed Web of Science ®Google Scholar
• Hwang B, Lee JH, Bang D. Author correction: single-cell RNA sequencing technologies and bioinformatics pipelines. Exp Mol Med 2021;53(5):1005. DOI:10.1038/s12276-021-00615-w. PubMed PMID: 34045654; PubMed Central PMCID: PMC8178331.
   PubMed Web of Science ®Google Scholar
• Morganti S, Tarantino P, Ferraro E, et al. Next generation sequencing (NGS): a revolutionary technology in pharmacogenomics and personalized medicine in cancer. Adv Exp Med Biol 2019;1168:9–30. DOI:10.1007/978-3-030-24100-1_2. PubMed PMID: 31713162.
   PubMed Web of Science ®Google Scholar
• McCarthy DJ, Campbell KR, Lun AT, et al. Scater: pre-processing, quality control, normalization and visualization of single-cell RNA-seq data in R. Bioinformatics. 2017;33(8):1179–1186. DOI:10.1093/bioinformatics/btw798. PubMed PMID: 28088763; PubMed Central PMCID: PMC5408845.
   PubMed Web of Science ®Google Scholar
• Stuart T, Butler A, Hoffman P, et al. Comprehensive integration of single-cell data. Cell. 2019;177(7):1888–1902. DOI:10.1016/j.cell.2019.05.031. PubMed PMID: 31178118; PubMed Central PMCID: PMC6687398.
   PubMed Web of Science ®Google Scholar
• Aran D, Looney AP, Liu L, et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat Immunol 2019;20(2):163–172. DOI:10.1038/s41590-018-0276-y. PubMed PMID: 30643263; PubMed Central PMCID: PMC6340744.
   PubMed Web of Science ®Google Scholar
• Yu G, Wang LG, Han Y, et al. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics. 2012;16(5):284–287. DOI:10.1089/omi.2011.0118. PubMed PMID: 22455463; PubMed Central PMCID: PMC3339379.
   PubMed Web of Science ®Google Scholar
• Dohner H, Wei AH, Lowenberg B. Towards precision medicine for AML. Nat Rev Clin Oncol. 2021;18(9):577–590. DOI:10.1038/s41571-021-00509-w. PubMed PMID: 34006997.
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447. DOI:10.1182/blood-2016-08-733196. PubMed PMID: 27895058; PubMed Central PMCID: PMC5291965.
   PubMed Web of Science ®Google Scholar
• van Galen P, Hovestadt V, Wadsworth Ii MH, et al. Single-cell RNA-Seq reveals AML hierarchies relevant to disease progression and immunity. Cell. 2019;176(6):1265–1281. DOI:10.1016/j.cell.2019.01.031. PubMed PMID: 30827681; PubMed Central PMCID: PMC6515904.
   PubMed Web of Science ®Google Scholar
• Information NCfB. MYB proto-oncogene, transcription factor [Homo sapiens (human)] National Library Medicine2022 [updated 5-Aug-2022].
   Google Scholar
• Wang JD, Zhou HS, Tu XX, et al. Prediction of competing endogenous RNA coexpression network as prognostic markers in AML. Aging. 2019;11(10):3333–3347. DOI:10.18632/aging.101985. PubMed PMID: 31164492; PubMed Central PMCID: PMC6555472.
   PubMedGoogle Scholar
• Xu Y, Milazzo JP, Somerville TDD, et al. A TFIID-SAGA perturbation that targets MYB and suppresses acute myeloid leukemia. Cancer Cell. 2018;33(1):13–28. DOI:10.1016/j.ccell.2017.12.002. PubMed PMID: 29316427; PubMed Central PMCID: PMC5764110.
   PubMed Web of Science ®Google Scholar
• Mill CP, Fiskus W, DiNardo CD, et al. Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2. Blood. 2022;139(6):907–921. DOI:10.1182/blood.2021013156. PubMed PMID: 34601571; PubMed Central PMCID: PMC8832475.
   PubMed Web of Science ®Google Scholar
• Klempnauer KH. C/EBPbeta sustains the oncogenic program of AML cells by cooperating with MYB and co-activator p300 in a transcriptional module. Exp Hematol 2022;108:8–15. DOI:10.1016/j.exphem.2022.01.003. PubMed PMID: 35032593.
   PubMed Web of Science ®Google Scholar
• Sancho M, Leiva D, Lucendo E, et al. Understanding MCL1: from cellular function and regulation to pharmacological inhibition. FEBS J 2021. DOI:10.1111/febs.16136. PubMed PMID: 34310025.
   PubMed Web of Science ®Google Scholar
• Ramsey HE, Fischer MA, Lee T, et al. A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia. Cancer Discov. 2018;8(12):1566–1581. DOI:10.1158/2159-8290.CD-18-0140. PubMed PMID: 30185627; PubMed Central PMCID: PMC6279595.
   PubMed Web of Science ®Google Scholar
• Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463(7283):899–905. DOI:10.1038/nature08822. PubMed PMID: 20164920; PubMed Central PMCID: PMC2826709.
   PubMed Web of Science ®Google Scholar
• Pei S, Pollyea DA, Gustafson A, et al. Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 2020;10(4):536–551. DOI:10.1158/2159-8290.CD-19-0710. PubMed PMID: 31974170; PubMed Central PMCID: PMC7124979.
   PubMed Web of Science ®Google Scholar
• Lasica M, Anderson MA. Review of venetoclax in CLL, AML and multiple myeloma. J Pers Med. 2021;11:6. DOI:10.3390/jpm11060463. PubMed PMID: 34073976; PubMed Central PMCID: PMC8225137.
   Web of Science ®Google Scholar
• Niu X, Zhao J, Ma J, et al. Binding of released Bim to Mcl-1 is a mechanism of intrinsic resistance to ABT-199 which can be overcome by combination with daunorubicin or cytarabine in AML cells. Clin Cancer Res. 2016;22(17):4440–4451. DOI:10.1158/1078-0432.CCR-15-3057. PubMed PMID: 27103402; PubMed Central PMCID: PMC5010519.
   PubMed Web of Science ®Google Scholar
• Quinn BA, Dash R, Azab B, et al. Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs. 2011;20(10):1397–1411. DOI:10.1517/13543784.2011.609167. PubMed PMID: 21851287; PubMed Central PMCID: PMC3205956.
   PubMed Web of Science ®Google Scholar
• Tron AE, Belmonte MA, Adam A, et al. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nat Commun. 2018;9(1):5341. DOI:10.1038/s41467-018-07551-w. PubMed PMID: 30559424; PubMed Central PMCID: PMC6297231.
   PubMed Web of Science ®Google Scholar
• Lee T, Bian Z, Zhao B, et al. Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitors. FEBS Lett 2017;591(1):240–251. DOI:10.1002/1873-3468.12497. PubMed PMID: 27878989; PubMed Central PMCID: PMC5381274.
   PubMed Web of Science ®Google Scholar
• GeneCards. JUN Gene – Jun Proto-Oncogene, AP-1 Transcription Factor Subunit GeneCardsSuite.
   Google Scholar
• GeneCards. JUNB Gene – JunB Proto-Oncogene, AP-1 Transcription Factor Subunit GeneCardsSuite. 2022.
   Google Scholar
• Vogt PK. Jun, the oncoprotein. Oncogene. 2001;20(19):2365–2377. DOI:10.1038/sj.onc.1204443. PubMed PMID: 11402333.
   PubMed Web of Science ®Google Scholar
• Romine KA, Nechiporuk T, Bottomly D, et al. Monocytic differentiation and AHR signaling as primary nodes of BET inhibitor response in acute myeloid leukemia. Blood Cancer Discov. 2021;2(5):518–531. DOI:10.1158/2643-3230.BCD-21-0012. PubMed PMID: 34568834; PubMed Central PMCID: PMC8462123.
   PubMedGoogle Scholar
• Fan SJ, Li HB, Cui G, et al. miRNA-149* promotes cell proliferation and suppresses apoptosis by mediating JunB in T-cell acute lymphoblastic leukemia. Leuk Res 2016;41:62–70. DOI:10.1016/j.leukres.2015.11.016. PubMed PMID: 26725775.
   PubMed Web of Science ®Google Scholar